Risk Intelligence Trends: How FDA Advertising Enforcement Is Raising the Bar for Pharma Social Media

The past year has challenged some long-held assumptions about pharma marketing. The FDA — particularly the Office of Prescription Drug Promotion (OPDP) — has taken a more assertive stance on advertising oversight across digital channels. Social and digital teams managing owned and operated channels have faced a series of regulatory actions: stricter scrutiny of digital ads, direct warning letters, and clear signals that regulators no longer distinguish between broadcast and digital when evaluating promotional activity.

For teams planning campaigns and scaling engagement, the core issue isn’t the regulations themselves. The underlying rules haven’t changed. What has changed is how consistently and publicly they are enforced. The question now facing pharma marketing teams is practical: how do you stay creative without crossing the line? 

The answer depends on understanding how regulators now evaluate digital campaigns in practice.

What FDA enforcement now expects from pharma digital teams

Regulatory scrutiny is rarely comfortable, but it exposes the gaps between how teams think their programs work and how they actually do. OPDP had issued enforcement letters in prior years, but 2025 marked a significant escalation. In September, the agency rolled out a wave of untitled letters focused on direct‑to‑consumer digital ads. What triggered them wasn’t necessarily major safety issues, but how channels were evaluated for transparency, balance, and accuracy — subtleties that often slip through in fast‑paced digital campaigns.

The pace only picked up through 2025. The FDA ultimately sent out 100 cease‑and‑desist letters targeting deceptive direct‑to‑consumer advertising, reinforcing what the September enforcement wave had already signaled: digital channels are now scrutinized with the same rigor as traditional broadcast advertising.

The September enforcement wave clarified another point teams can no longer afford to misinterpret — sponsored content of any kind falls under the same scrutiny as “traditional” ads. Whether it’s a celebrity post, a sponsored TikTok, or a physician sharing clinical commentary, regulators no longer distinguish by format. If your brand is behind it, you’re responsible for it.

The year brought other sources of complexity as well. The ACIP’s updated vaccine guidance raised the bar for how public health information could be communicated, forcing digital teams to adapt quickly while maintaining compliance.

Taken together, the message is consistent: regulators now approach digital platforms with the same seriousness as legacy broadcast channels. The teams navigating this shift most effectively aren’t pulling back. They’re investing in monitoring and moderation solutions that actually hold up under scrutiny.

What you publish matters, but regulators also pay attention to what happens after a campaign goes live. Comment threads, sponsored posts, and influencer campaigns can all surface misleading claims, adverse events, or off-label discussion. The real test is whether your monitoring holds up at midnight on a holiday weekend as well as it does on a Tuesday afternoon.

Three things worth examining in your current post-launch process

Given this level of scrutiny, digital and social teams need to challenge their assumptions and put workflows to the test. Here are three areas demanding close attention:

What happens if a DOL (Digital Opinion Leader) posts an edited caption at midnight during a holiday weekend? The best teams have an answer to that question, because regulatory scrutiny doesn’t adjust to your business hours, and neither does your audience.

High-traffic campaigns move fast, and coverage needs to move with them. Teams that engage most confidently online are the ones who’ve built monitoring processes that hold up around the clock — consistent, predictable, and resilient regardless of time zone, language, or campaign volume.

Most teams feel confident about their owned channels, where processes and oversight are typically well-established. The gaps tend to show up in paid and sponsored content, like boosted posts, DOL campaigns, and comment threads on influencer content where oversight is less consistent and coverage is easier to assume than verify. 

The real question isn’t whether you have a process for monitoring and moderating your digital channels. It’s whether that process holds up across every channel, at every hour, in every market you operate in. A post that goes unmoderated overnight in a foreign market carries the same risk as one that slips through during a busy campaign launch. If your monitoring relies on a regional team that clocks out at 5 pm, or a tool that flags keywords but doesn’t understand pharma context, those gaps are harder to defend than they might seem. 

The brands that engage most confidently online aren’t the ones who’ve restricted their activity — they’re the ones who’ve built coverage they can actually trust. That means knowing every sponsored post is being reviewed, every comment thread is being watched, and every channel reflects the same standard your own properties do.

The 2025 enforcement wave left no ambiguity: if you pay for content, you’re responsible for everything associated with it. That responsibility extends beyond the initial post to the ensuing discussion and any adverse events mentioned in comments.

Plenty of teams treat DOL channels as less formal, as if those platforms are “rented land.” That’s no longer sustainable. To avoid false claims, expert context and representation matter. Monitoring, escalation, and documentation must be as rigorous for sponsored creator partnerships as they are for your own channels.

Expanding influencer programs this year? Get the 6-step Pharma DOL Campaign Compliance Checklist to align your team before launch.

Why FDA enforcement isn’t an argument for pulling back

So, does tougher enforcement mean it’s time to back away from digital? The numbers — and real-world experience — say no.

Regulators aren’t looking for silence or disengagement, but they now expect your marketing to be transparent and defensible. If your team has solid, well-documented workflows that you repeat and validate consistently, you’ll be in a much stronger spot when audit time comes around. Spot checks and reactive monitoring might seem helpful, but too often, they just aren’t enough under close inspection.

Pulling back from communication means letting go of your seat at the table. In digital channels, misinformation spreads fast — sometimes before your brand can even get a word in. If your voice isn’t there, someone else will fill the gap. That’s how critical questions and details get lost, leaving patients, HCPs, and the public with confusion or incomplete information.

Don’t hit pause — take a closer look. Are you sure every channel is covered? Can you track every post and interaction for risks? Staying engaged, while staying compliant and transparent, isn’t just good practice. It protects your brand and serves your audience, all at once.

How pharma teams should approach engagement under tighter scrutiny

There’s no substitute for being ready — and today, readiness is judged by how well your post‑launch workflows hold up under scrutiny. With enforcement now squarely focused on digital channels, this is the right moment to take a hard look at whether your monitoring and escalation processes actually hold up in practice.

Start by asking the tough questions:

• Can you show when comments are disputing marketing claims on your channels?
• Do you have consistent coverage for reviewing and monitoring DOL campaigns across time zones and launch periods?

Resolver supports pharma teams with continuous monitoring across owned, paid, and sponsored social channels — including Digital Opinion Leader programs — so post‑launch activity doesn’t become a blind spot. The High‑Stakes Influence guide offers practical frameworks to help teams assess where coverage holds up, and where assumptions may need to be pressure‑tested.